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ABSTRACT
Rhabdomyosarcoma (RMS) is the most common childhood soft tissue sarcoma. 
RMS often arise from myogenic precursors and displays a poorly differentiated 
skeletal muscle phenotype most closely resembling regenerating muscle. GSK3β 
is a ubiquitously expressed serine-threonine kinase capable of repressing the 
terminal myogenic differentiation program in cardiac and skeletal muscle. Recent 
unbiased chemical screening efforts have prioritized GSK3β inhibitors as inducers of 
myodifferentiation in RMS, suggesting efficacy as single agents in suppressing growth 
and promoting self-renewal in zebrafish transgenic embryonal RMS (eRMS) models in 
vivo. In this study, we tested the irreversible GSK3β-inhibitor, tideglusib for in vivo 
efficacy in patient-derived xenograft models of both alveolar rhabdomyosarcoma 
(aRMS) and eRMS. Tideglusib had effective on-target pharmacodynamic efficacy, but 
as a single agent had no effect on tumor progression or myodifferentiation. These 
results suggest that as monotherapy, GSK3β inhibitors may not be a viable treatment 
for aRMS or eRMS.
INTRODUCTION
Rhabdomyosarcoma (RMS) is the most common 
childhood soft tissue sarcoma and is broadly classified 
into two histologic subtypes: alveolar rhabdomyosarcoma 
(aRMS) and embryonal rhabdomyosarcoma (eRMS). 
aRMS is a highly aggressive tumor is characterized by the 
pathogenomic t(1:13) or t(2:13) translocation resulting 
in the chimeric gene-fusion product PAX3:FOXO1 or 
PAX7:FOXO1, respectively [1]. eRMS is often defined 
as a RAS driven tumor [2-4]. RMS has been shown 
experimentally to have a myogenic cell-of-origin in 
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some model systems and displays a poorly differentiated 
phenotype with gene expression profiles similar to fetal 
or regenerating muscle [5, 6]. Despite the expression 
of myogenic differentiation-specific transcription 
factors MYOD1 and myogenin, RMS fails to terminally 
differentiate [7].
Glycogen synthase kinase 3β (GSK3β) is a 
ubiquitously expressed serine-threonine kinase involved 
in the suppression of skeletal muscle myogenesis and 
cardiomyocyte hypertrophy via repression of MEF2 
transcriptional activity and p38/MAPK signaling [8]. 
In myoblasts, inhibition of GSK3β induces muscle 
differentiation [9, 10]; thus, pharmacologic inhibition of 
GSK3β has been suggested to be a possible therapeutic 
avenue towards myodifferentiation in RMS [11].
To this end, recent studies have explored molecularly-
targeted therapies that overcome the impaired differentiation 
in rhabdomyosarcoma [12-15]. A report from our group 
using unbiased chemical screens prioritized GSK3β 
inhibitors as inducers of myogenic differentiation in eRMS 
[11]. In this study, we investigated the expression levels of 
GSK3α and GSK3β at the mRNA and protein level in RMS 
patient samples, RMS cell lines, and normal samples. In 
addition, we examined the in vivo effect of pharmacologic 
GSK3β inhibition in aRMS and eRMS.
RNA-Seq data revealed significant differences 
in the expression of GSK3α/β (and its splice variants) 
in aRMS and eRMS. We then tested the preclinical 
efficacy of tideglusib, an irreversible inhibitor of 
GSK3β [16] in patient-derived xenograft (PDX) models 
of eRMS and aRMS. In vivo, tideglusib had no effect 
on tumor progression or myodifferentiation, although 
pharmacodynamic examination showed efficient reduction 
in GSK3β mediated phosphorylation of β-catenin at Ser33/37 
and Thr41 and consequent stabilization of β-catenin [17].
RESULTS
Comparison of GSK3α and GSK3β expression 
in normal muscle and RMS cell lines and patient 
samples
GSK3 is a serine-threonine kinase that exists as 
two isoforms encoded by two distinct genes: GSK3α 
and GSK3β [18]. These isoforms are structurally similar 
(Figure 1A) but functionally different and exhibit distinct 
phenotypes [18]. GSK3α/β contain a protein kinase 
domain with phosphorylation of Tyr (Y279/216) facilitating 
its catalytic activity and phosphorylation of Ser21/9 
inhibiting its own activity [19, 20] (Figure 1A). Although 
GSK3α exists as GSK3α1/α2/α3/α4, these variants are 
rarely specified in literature. GSK3α1/α3 contains an open 
reading of 483 amino acids each encoding a protein of 
51 KDa. GSK3α2 contains an open reading of 401 amino 
acids encoding a protein of 45 KDa which has not been 
studied in detail. GSK3α4 does not form protein [http://
www.ensembl.org/Homo_sapiens/Gene/Summary?db=co
re;g=ENSG00000105723;r=19:42230186-42242625].
Similarly, GSK3β exist as spliced variants GSK3β1/
β2/β3/β4 (Figure 1A). GSK3β1 is a predominantly 
expressed spliced variant with GSK3β2 generally 
accounting for only 15% of total expression [19]. GSK3β3/
β4 does not form protein [http://uswest.ensembl.org/Homo_
sapiens/Gene/Summary?db=core;g=ENSG00000082701
;r=3:119821323-120094417].GSK3β2 has 13 additional 
amino acids inserted in the catalytic (kinase) domain [19] 
(Figure 1A); however, both GSK3β1 and GSK3β2 have 
similar phosphorylation patterns at the regulatory sites 
Ser9 and Tyr216. GSK3β1/β2 exhibits preferential activity 
towards specific substrates; for example, GSK3β2 has 
reduced kinase activity towards the microtubule associated 
protein tau (Ser396), phospho-glycogen synthase 2 peptide, 
CRMP2 (Thr509/514), CRMP4 (Thr509) and Inhibitor-2 (Thr72) 
compared to GSK3β1 [20-21].
To begin the preclinical validation of further preclinical 
studies of GSK3β inhibition in RMS, we investigated the 
incidence of GSK3α and GSK3β expression in RMS. From 
a published RNA- Seq data [22], we examined GSK3α/β 
expression in 31 RMS cell lines (17 aRMS, 14 eRMS), 105 
RMS patient samples (38 aRMS, 67 eRMS) and 19 normal 
muscle tissue samples. RMS sample and normal sample 
expression data are presented as a heatmap partitioned into 
disease subtype and splice variants in Figure 1B. Overall, 
RNA expression of GSK3α and GSK3β statistically differs 
amongst sample type (RMS patient samples, RMS cell lines, 
normal muscle samples) and disease type (aRMS, eRMS). 
GSK3α1 and GSK3β1 both had high expression across 
aRMS/eRMS patient samples, cell lines and normal muscle 
(Figure 1B & 1C). GSK3α2 is expressed at increased level 
by patient samples compared to cell lines and normal muscle, 
whereas GSKα3 is expressed at lower levels across patient 
samples and cell lines (Figure 1B & 1C). GSK3α4, which has 
no protein, is expressed at the RNA level in patient samples. 
Interestingly, GSK3α2 has no conserved serine amino acid 
at position twenty one unlike GSK3α1/α3. Phosphorylation 
of Ser21 inhibit GSK α1/α3 activity, raising the question 
whether GSK3α2 expression in aRMS and eRMS patients 
could be related to oncogenesis or progression. Among 
GSK3β, GSK3β2 is expressed at high levels in cell lines 
and low in patient samples. Similarly, GSK3β4 which has 
no protein is expressed at high levels in cell lines but at low 
levels in patient samples. The GSK3β3 splice variant, which 
has no protein, was expressed at low levels across aRMS/
eRMS patient samples and cell lines (Figure 1B & 1D). 
Overall, GSK3α1 and GSK3β1 that are expressed most 
consistently at high levels across cell lines/patient samples 
(Figure 1B & 1C & 1D).
To compare co-expression of GSK3α and GSK3β 
between RMS patient samples, cell lines, and normal 
muscle samples for aRMS and eRMS, we measured 
correlation coefficients of GSK3α and GSK3β expression 
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between samples (Supplementary Figure 1). The co-
expression of GSK3α and GSK3β is statistically different 
(i.e., unlinked) amongst all sample types in aRMS (cell 
lines vs. patient tumors p = 1.38e-17, cell lines vs. normal 
samples p = 2.05e-9, patient tumors vs. normal samples 
p = 4.04e-15) and eRMS (cell lines vs. patient tumors p = 
2.63e-20, cell lines vs. normal samples p = 1.02e-5, patient 
tumors vs. normal samples p = 4.3e-17) per Hotelling’s T2 
Figure 1: GSK3α and GSK3β expression in RMS cell lines, patient samples, and normal muscle. (A) Schematic representation 
of full length GSK3α1/α2/α3 and GSK3β1/β2 showing their catalytic domain (kinase), sites of serine (S) and tyrosine (Y) phosphorylation. 
(B) RNA sequencing was performed on 31 RMS cell lines, 105 RMS patient samples, and 19 normal muscle tissue samples and the 
resulting Log2-scaled RPKM values for 4 isoforms of GSK3α and GSK3β are shown. Different sample types (RMS cell line, RMS patient 
sample, normal muscle) are indicated by the color-coded bars at the top of the figure. The heat scale is given on the side, ranging from green 
(low expression; RPPKM = -3), to black (RPKM = 0), to red (high expression; RPKM=3).(C & D) Table showing the different spliced 
variant of GSK3α and GSK3β with their respective ensemble ID, gene symbol, protein length (a.a) and their expression across, aRMS, 
eRMS patient samples and cell lines (color code matching heat map above). (E) Western blotting showing pattern of GSK3 α/β expression 
across aRMS, eRMS, or primary tissue versus cell line samples. GSK3α and GSK3β have molecular weight of 51 and 47 KDa.
Oncotarget62979www.impactjournals.com/oncotarget
test. MANOVA statistical analysis revealed GSK3α and 
GSK3β expression is uncorrelated amongst individual 
samples and across sample types (GSK3α samples 
p = 2.5e-8, type p = 2.2e-7, GSK3β samples p = 1.7e-13, type 
p = 2.1e-14) (Figure 1B, Supplementary Figure 1).
To assess if GSK3α/β expression is correlated with 
clinical outcome, we surveyed a publicly available clinical 
dataset [23] to analyze the expression of each gene in 
two patient segments (fusion-positive RMS and fusion-
negative RMS) with the corresponding survival of the 
patient segments (Supplementary Figure 2, Supplementary 
Table 1). GSK3α/β expression was generated using 
Affymetrix U95 Gene Chip microarrays, and thus is a unit 
less measure of gene expression. Only in fusion-positive 
RMS, GSK expression correlated with statistically 
significant difference in patient survival, with low versus 
high GSK3β expression (threshold = 170) showing 
statistical significance (p = 0.04) in patient outcome across 
23 patients (Supplementary Figure 2D). Higher expression 
of GSK3β correlated with improved outcome in the aRMS 
patients.
To identify a representative xenograft model 
system, we performed western blot analysis of expression 
of GSK3α/β in aRMS/eRMS cell lines and PDX tumor 
cultures (Figure 1E). High GSK3α/β co-expression was 
seen in aRMS primary tumor culture PCB380 and eRMS 
primary tumor culture PCB82 in comparison to aRMS 
cell lines Rh30 and eRMS cell lines RD and Rh18. RNA-
Seq data (GEO Accession number GSE100427) revealed 
higher expression of GSK3α1/β1 compared to other splice 
variants in PCB380/82 (Supplementary Tables 2 & 3 & 
4 & 5). Thus, PDX models PCB380 and PCB82 were 
selected as model systems for further studies.
Tideglusib shows pharmacological efficacy 
in vitro
To test the pharmacological activity of tideglusib 
against GSK3β, PDX derived cell cultures PCB82 (eRMS) 
and PCB380 (aRMS) were treated with tideglusib at its 
previously reported enzyme IC50 of 60 nM, which has 
been shown to bring irreversible inhibition of kinase 
activity of GSK3β (in cell free assay) [16]. After twenty 
minutes, cells were harvested and analyzed for the GSK3β 
mediated phosphorylation status of β–catenin, which was 
reduced substantially upon treatment. A corresponding 
increase in total levels of β–catenin was also observed 
which indicated the efficacy of tideglusib in blocking 
GSK3β activity (17) (Figure 2A & 2B).
Tideglusib shows no in vivo effect on survival or 
myodifferentiation
We performed preclinical testing of tideglusib 
in PDX mouse models of aRMS (PCB380) and eRMS 
(PCB82). The maximum tolerated dose (MTD) of 
tideglusib was determined experimentally and found to 
be 200 mg/kg (data not shown). No significant toxicity 
(weight loss, activity change) was observed at this dose.
Tumor-bearing mice were treated with 200 mg/kg 
of tideglusib daily by oral gavage. Kaplan-Meier survival 
analysis showed no significant differences in survival 
between Group 1 and Group 2 (PCB82 eRMS treated with 
vehicle vs tideglusib, p = 0.972) or Group 3 and Group 4 
(PCB380 aRMS treated with vehicle vs tideglusib, p = 0.612) 
(Figure 2C). Pharmacodymanic analysis showed significant 
reduction in the GSK3β mediated phosphorylation of 
β-catenin and an increase in total β-catenin in tumor lysates 
(Figure 2D & 2E) in both eRMS (p = 0.038) (Figure 2F; 
upper panel) and aRMS model (p = 0.024) (Figure 2F; 
lower panel) demonstrating that tideglusib treatment inhibits 
catalytic activity of GSK3β but does not improve survival.
We also examined the effect of tideglusib on 
myodifferentiation. Immunohistochemistry on treat-
ment and control groups from both aRMS and eRMS 
PDX model did not exhibit any rhabdomyoblasts 
(Supplementary Figure 3 & Supplementary Table 6). 
Western blot analysis of tideglusib-treated aRMS and 
eRMS PDX tumor protein lysates showed no induction of 
myodifferentiation (via myosin heavy chain expression) 
in treated versus control groups. Differentiated human 
skeletal myoblasts (HSMM) were used as a positive 
control (Figure 2G & 2H). Following tideglusib treatment, 
myogenin was downregulated in eRMS (Figure 2G), and 
aRMS (Figure 2H). Overall, tideglusib had no effect on 
survival or myodifferentiation.
DISCUSSION
To our knowledge this is the first study 1) to analyze 
the expression of GSK3α/β and its splice variants across a 
broad collection of RMS cell lines and patient samples in 
comparison to normal muscle samples, and 2) to examine 
pharmacological inhibition of GSK3β in PDX RMS 
models.
Tideglusib, an irreversible inhibitor of GSK3β, was 
tested for preclinical efficacy against RMS PDX models. 
Tideglusib displayed pharmacokinetic potency in reducing 
GSK3β-mediated phosphorylation of phospho-β-catenin 
and consequent increase in total β-catenin in vitro for 
primary tumor cultures with demonstrated over-expression 
of GSK3α and GSK3β. Despite this on-target efficacy, 
tideglusib tested at the highest dosage (200 mg/kg) had 
no effect on in vivo tumor growth or myodifferentiation in 
PDX models of aRMS or eRMS. Unexpectedly, tideglusib 
treatment showed reduction in myogenin in aRMS/eRMS 
PDX tumor. This is surprising as recent study shows that 
myogenin function in aRMS is disrupted by sustained 
GSK3β kinase activity contributing to the undifferentiated, 
proliferative phenotype [13]. However, the difference in 
observation could be attributed to the fact that this study 
is limited to one aRMS cell line, Rh30. Our studies of 
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Figure 2: Effects of tideglusib on tumor growth, myodifferentiation in vivo. (A & B) Western blotting of vehicle and tideglusib 
treated human PDX derived primary culture (PCB82 and PCB380) for detection of GSK-3β mediated phosphorylation of β-catenin which 
showed reduction and an increase in total β-catenin. (C) Kaplan-Meier curve showing eRMS (PCB82) and aRMS mice (PCB380) treated 
with 200 mg/kg tideglusib via oral gavage daily experienced no effect on survival. (D & E) Western blotting of vehicle and tideglusib 
treated human PDX tumors (PCB82 and PCB380) for detection of GSK3β mediated phosphorylation of β-catenin which showed reduction 
and an increase in total β-catenin. (F) Densitometric analysis shows the reduction in phos-β-catenin upon tideglusib treatment in eRMS 
(PCB82) (upper panel) and aRMS (PCB380) (lower panel) to be statistically significant (*p>0.05; **p>0.001). Error bars represent mean 
± S.D. (G & H) Western blotting of vehicle and tideglusib treated human PDX derived primary culture (PCB82 and PCB380) for detection 
of myogenin and myosin heavy chain (MHC). Differentiated HSMM used as a positive control.
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GSK3α/β isoform expression suggest that cell lines have 
a skewed isoform and splice variant expression compared 
to primary tumor tissue, which is important to take into 
account. Our findings also suggests that GSK3β is not 
the optimal therapeutic target for single-agent treatment 
of aRMS/eRMS. Yet while tideglusib may be of limited 
value as a monotherapy in RMS, future studies could 
explore combination therapies with chemotherapy 
agents. Furthermore, since GSK3 is regulated by multiple 
pathways, new roles of GSK3α and GSK3β, under non-
homeostatic ‘stress’ conditions may be uncovered.
MATERIALS AND METHODS
Cell culture
aRMS cell line Rh30, eRMS cell lines RD and Rh18, 
and PDX cultures PCB380 and PCB82 were cultured in 
growth medium (GM) RPMI 1640 (11875-093; Thermo 
Fisher Scientific, Waltham, MA, USA) supplemented 
with 10% fetal bovine Serum (FBS) (26140079; Thermo 
Fisher Scientific) and 1% penicillin/Streptomycin (15140-
122; Thermo Fisher Scientific). Primary human skeletal 
myoblasts (HSMM) (CC-2580; Lonza Inc, Allendale, NJ, 
USA) were cultured in GM (SKBM-2 CC-3244; Lonza 
Inc) supplemented with 10% FBS and 1% penicillin/
streptomycin. HSMM was differentiated until day 4 in 
differentiation medium DM: F-12 (11320033; Thermo 
Fisher Scientific). All cells were incubated at 37˚c and 
5% CO2. aRMS and eRMS cell lines were authenticated 
by short tandem repeat (STR) analysis (Biosynthesis, 
Lewisville, TX, USA).
Tideglusib cell treatments
Tideglusib, an irreversible inhibitor of GSK3β was 
purchased from SelleckChem (S2823, Houston, TX, USA). 
aRMS and eRMS PDX primary tumor cell cultures were 
treated with tideglusib at its IC50 for GSK3β (60 nM) [16].
Patient-derived xenograft models
RMS samples were collected from patients 
undergoing planned surgical resection or research-autopsy 
enrolled in the bio-banking and model development 
program Childhood Cancer Registry for Familial and 
Sporadic Tumors (CuRe-FAST). All patients provided 
informed consent; patient data and clinical and pathologic 
findings are maintained in a de-identified database. All 
aspects of the study were reviewed and approved by the 
Oregon Health & Science University Institutional Review 
Board and the Children’s Cancer Therapy Development 
Institute Institutional Review Board. The eRMS PDX 
PCB82 (TM00360) was recently described [24], and the 
Pax3:Foxo1+ aRMS PDX model PCB380 (TM01165) was 
similarly established from an untreated, surgically-resected 
soleus tumor from a 2-year-old female. To establish each 
PDX model, NSG (NOD.Cg-Prkdcscid IL2rgtm1Wjl/SzJ) mice 
were obtained by The Jackson Laboratory. Tumor fragments 
were obtained from the aforementioned patients and 
implanted into the rear flanks of recipient female NSG (JAX 
# 5557) mice using a trochar. Once tumors reached 1cc, they 
were collected and fragmented for serial transplantation in 
NSG mice to create low-passage cohorts for future studies. 
All studies were done with the approval of The Jackson 
Laboratory IACUC. For tissue culture work, PCB380 and 
PCB82 were authenticated by analysing for the expression 
of myogenin and lack of MHC expression.
Generation of RNA-Seq data
RNA sequencing data has been previously described 
[22].
Western blot
To prepare protein lysate, tumors and PDX cell lines 
PCB82 and PCB380 treated with vehicle (control) and 
tideglusib were lysed in radio immunoprecipitation (RIPA) 
buffer (89901, Thermo Fisher Scientific) containing both 
protease and phosphatase inhibitors (Sigma Aldrich, St. 
Louis, MO). Lysates were homogenized and clarified 
by centrifugation at 14,000 rpm for 10 minutes. Thirty 
μg of protein were electrophoresed in 7.5-10% mini 
protean polyacrylamide gel (4561024, Bio-Rad, Hercules, 
CA, USA) transferred to PVDF membranes (1620255, 
Bio-Rad) for immunoblot analysis with anti-GSK3α/β 
(sc-7291, Santa Cruz Biotechnology, Dallas, TX, USA) 
(the monoclonal antibody used is raised against the amino 
acid 1-420 representing the full length GSK3β), anti-
Phos-β-Catenin (9561, Cell Signaling, Danvers, MA, 
USA), anti-β-Catenin (9562, Cell Signaling), anti-MHC 
(MAB4470, R&D systems, Minneapolis, MN, USA), 
anti-myogenin (sc-576, Santa Cruz Biotechnology), anti-
β-actin (ab8227, Abcam, San Francisco, CA, USA). Blots 
were developed using FluorChem Q system (92-14095-00, 
protein simple, San Jose, CA, USA).
Xenograft studies
Tideglusib was dissolved in 30% PEG400/0.5% 
Tween80/5% propylene glycol, 30 mg/mL and formulated for 
in vivo testing in 26% PEG400 (Polyethylene Glycol 400), 
15% Cremophor EL. The MTD of tideglusib was determined 
experimentally. Mice (n=3 per arm) were randomized to 100, 
150, or 200 mg/kg treatment arms. Mice were dosed by oral 
gavage daily for 21 days. Clinical observations of general 
behavior, mobility, and weight loss were performed daily. 
MTD was defined as the dosage that causes a mean weight 
loss of >20% as a group or a body condition of <2 for one 
or more animals in a group. For PDX preclinical efficacy 
studies, forty-eight 5-6 week old NSG mice were obtained 
from The Jackson Laboratories. Twenty-four mice were 
trochar implanted with a passage 1-3 PDX fragment in the 
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right hind flank to generate study mice. Mice were monitored 
twice weekly for clinical observations and body weight. 
Tumor-bearing mice were randomized into treatment cohorts 
of n=6 mice per group so that the mean cohort tumor volume 
was 200-300 cc. Mice were treated with vehicle or tideglusib 
administered by oral gavage at a dose of 200 mg/kg daily 
until tumors reached 2000 cc or the condition of the mice 
precluded ongoing treatment.
Statistical analysis
The tumor endpoint volumes for time-to-event 
(TTE) analysis were set at 1500 mm3 and 2000 mm3, in the 
tideglusib study. TTE was defined in days by selecting the 
day in which the tumor volume equaled or surpassed 1500 
mm3 and 2000 mm3. Animals that did not reach endpoint 
volume were assigned a TTE of 58 days. Comparisons were 
analyzed by One-way Anova with Bonferroni’s post-test. 
The Kaplan-Meier survival plot represents the percentage of 
animals surviving at different time points during the study. 
These percentages were generated from the TTE data using 
GraphPad Prism 6.0 software. Survival curve comparisons 
were analyzed by the Mantel-Cox and Gehan-Breslow-
Wilcox tests (95% CI) through Graph Pad Prism software. 
For densitometric analysis, significance was determined 
by a one-tailed Student’s t test and p values of <0.05 
were considered to be statistically significant. Statistical 
significance were set at * P < 0.05 and **P < 0.01. Error 
bars indicate mean ± standard deviation (SD).
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